- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01292499
Italian Network for the Improvement of Compliance in Depression
February 8, 2011 updated by: Ospedale Amedeo di Savoia
The RIMAT-De study (Rete Italiana per il Miglioramento dell'Adesione al Trattamento nella Depressione) is a multicentric Randomized Controlled Clinical Trial aiming at identifying the best strategies available to reduce the poor compliance of patients with antidepressant drugs.
Patients' compliance will be measured within six months of pharmacological treatment, comparing the specific contributions of brief psychotherapy and psychoeducational interventions: the psychoeducational intervention will encompass the monitoring of drugs' side effects and patients' satisfaction.
In the rest of the document, for the sake of brevity the two treatments previously described will be indicated as "psychotherapy" and "psychoeducation".
These treatments will be compared with the treatment usually carried on by the mental health centers involved (i.e.
treatment as usual, TAU).
The factorial design of the study will take into consideration the combination of the two treatments (i.e.
psychotherapy and psychoeducation) as well.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Another important aim of the study is the investigation of whether the clinical improvement depends on the efficacy of the psychological treatments proposed per se, or whether they just contribute to increase the compliance with the pharmacological treatment, maintaining the patients on treatment longer and allowing the drugs to reach long-lasting effects.
While recognizing the general therapeutic efficacy of psychotherapy in the treatment of depressive disorders, nevertheless the present study aims at verifying whether an equal therapeutic effect may be reached via a better compliance with the pharmacological treatment, fostered for example by the psychoeducational intervention.
The rationale lays on the ease of transferability of psychoeducational interventions to the general clinical practice, that usually suffers from lack of resources in implementing structured psychotherapy interventions.
Study Type
Interventional
Enrollment (Anticipated)
1264
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Carmine Munizza
- Phone Number: 00390114395803
- Email: cmunizza@tin.it
Study Locations
-
-
-
Torino, Italy, 10149
- Recruiting
- ASL TO2 Amedeo di Savoia
-
Contact:
- Carmine Munizza
- Phone Number: 00390114395803
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- New episode of depression, according to the DSM-IV (Codes F32 Major Depressive Disorder, single episode; F33 Major Depressive Disorder, recurrent; F34.1 Dysthymic Disorder; F32.9 Depressive Disorder, not otherwise specified), or new contact with the Mental Health Center for recurrent depression (same Codes) after a six-month period (or longer) without any treatment;
- Age >= 18 years old;
- QIDS-SR16 score >=10;
- Necessity of a pharmacological antidepressant treatment;
- Written informed content given by the participant before the beginning of the study.
Exclusion Criteria:
- Comorbidity of schizophrenic disorder, according to the DSM-IV (Codes F06.3 - Organic mood disorder; F20 - Schizophrenia; F29 -Uunspecified Nonorganic Psychosis; F30-F31 - Manic Episode and Bipolar Affective Disorder; F34.0 - Cyclothymia; F10-F19 - Mental and Behavioural Disorders due to Psychoactive Substance Use).
- Current pregnancy.
- Probable hospitalization, for whatever reason.
- Patient seen once and then referred to his/her GP or other specialist physician;
- Pharmacological treatment already prescribed by a psychiatry or neurology specialist. However, if the patient is not satisfied with the current treatment and/or the psychiatrist involved in the present study considers appropriate to change the treatment, the present exclusion criterion will not be valid any longer.
- Pharmacological treatment prescribed for more than 15 days by patient's GP. However, if the patient is not satisfied by the treatment and/or the psychiatrist involved in the present study considers appropriate to change the treatment, the present exclusion criterion will not be valid any longer.
- The patient is currently under psychotherapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Pharmacological treatment
Pharmacological treatment consists of the administration of a single antidepressant drug.
The treatment will be administered as currently done by the mental health center, taking into due account patient's age, general health, previous response to antidepressant drugs, comorbidity, and potential side effects of drugs.
|
|
Experimental: Psychotherapy
Will receive psychotherapy as well (10 sessions).
Psychoterapy will consist of 10 weekly sessions, lasting about 50 minutes each.
Psychotherapy will begin after 4-6 weeks from the beginning of the pharmacological treatment, to allow drugs to be effective.
The overall list of visits scheduled for the patients is defined during the second psychiatric visit, to allow a reasonable planning of all of the appointments required for that particular patient.
Psychotherapists will be free to follow the approach they were trained.
|
10 sessions (50 min)
|
Experimental: Psychoeducation
Will receive psychoeducation as well, with phone monitoring and regular follow-ups.
Psychoeducation does not simply mean making the patient aware of depression etiology and drugs effect.
In fact, patients should receive additional counselling about how to integrate the pharmacological treatment in their daily routine and to solve possible problems, in order to allow them to be actively and constantly involved in the treatment they are going to receive.
Patients will receive 7 sessions of psychoeducation and 7 phone calls during the first 5 months.
In addition, all of the patients will receive a brochure explaining the most important aspects of their disorder.
|
7 sessions + 7 phone calls
|
Experimental: Psychoeducation and psychotherapy
Will receive both psychoeducation and psychotherapy sessions.
|
Psychoeducation + psychotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients showing good compliance, as measured at six months from the beginning of the treatment.
Time Frame: 3 years
|
The effect size is conceptualized as the difference between the proportion of patients in the 4 treatment arms showing good compliance at the end of the study.
The effects of the two treatments (psychotherapy and psychoeducation) will be measured separately, via stratified analyses and multivariate regression models, as appropriate.
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2009
Primary Completion (Anticipated)
January 1, 2012
Study Completion (Anticipated)
July 1, 2012
Study Registration Dates
First Submitted
January 26, 2011
First Submitted That Met QC Criteria
February 8, 2011
First Posted (Estimate)
February 9, 2011
Study Record Updates
Last Update Posted (Estimate)
February 9, 2011
Last Update Submitted That Met QC Criteria
February 8, 2011
Last Verified
December 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RIMAT-De
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Psychotherapy
-
Universidade Federal do Rio de JaneiroCompleted
-
Randi UlbergUniversity of OsloCompleted
-
Hopital MontfortThe Ottawa HospitalCompletedDepression | Parkinson's DiseaseCanada
-
Marianne Lau, MD, DSci.The Ministry of Science, Technology and Innovation, DenmarkUnknownBulimia Nervosa (BN) | Binge Eating Disorder (BED) | Eating Disorder Not Otherwise Specified (EDNOS)Denmark
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Completed
-
University Hospital FreiburgCompletedChronic Major Depressive DisorderGermany
-
Oslo University HospitalSouth-Eastern Norway Regional Health AuthorityUnknown
-
Memorial Sloan Kettering Cancer CenterUniversity of Manitoba; National Cancer Institute (NCI); Visiting Nurse Service... and other collaboratorsCompleted
-
Centre Hospitalier Régional Metz-ThionvilleCentral Hospital, Nancy, France; University of LorraineCompletedBreast Cancer FemaleFrance
-
Weill Medical College of Cornell UniversityUnknownIdentity Pathology | Behavior ProblemsUnited States